The Electrophysiology Professional Interest Area (EPIA) and Global Brain Consortium endorsed recommendations on candidate EEG measures for Alzheimer’s disease (AD) clinical trials. The Panel reviewed the field literature. As most consistent findings, AD patients with mild cognitive impairment and dementia showed abnormalities in peak frequency, power, and “interrelatedness” at posterior alpha (8-12 Hz) and widespread delta (<4 Hz) and theta (4-8 Hz) rhythms in relation to disease progression and interventions. The following consensus statements were subscribed: (i) Standardization of instructions to patients, rsEEG recording methods, and selection of artifact-free rsEEG periods are needed; (ii) Power density and “interrelatedness” rsEEG measures (e.g., directed transfer function, phase lag index, linear lagged connectivity, etc.) at delta, theta, and alpha frequency bands may be use for stratification of AD patients and monitoring of disease progression and intervention; and (iii) International multisectoral initiatives are mandatory for regulatory purposes.

Measures of Resting State EEG Rhythms for Clinical Trials in Alzheimer’s Disease: Recommendations of an Expert Panel / Babiloni, Claudio; Arakaki, Xianghong; Azami, Hamed; Bennys, Karim; Blinowska, Katarzyna; Bonanni, Laura; Bujan, Ana; Carrillo, Maria C.; Cichocki, Andrzej; de Frutos-Lucas, Jaisalmer; DEL PERCIO, Claudio; Dubois, Bruno; Edelmayer, Rebecca; Egan, Gary; Epelbaum, Stephane; Escudero, Javier; Evans, Alan; Farina, Francesca; Fargo, Keith; Fernández, Alberto; Ferri, Raffaele; Frisoni, Giovanni; Hampel, Harald; Harrington, Michael G.; Jelic, Vesna; Jeong, Jaeseung; Jiang, Yang; Kaminski, Maciej; Kavcic, Voyko; Kilborn, Kerry; Kumar, Sanjeev; Lam, Alice; Lim, Lew; Lizio, Roberta; Lopez, David; Lopez, Susanna; Lucey, Brendan; Maestú, Fernando; Mcgeown, William J.; Mckeith, Ian; Vito Moretti, Davide; Nobili, Flavio; Noce, Giuseppe; Olichney, John; Onofrj, Marco; Osorio, Ricardo; Parra-Rodriguez, Mario; Rajji, Tarek; Ritter, Petra; Soricelli, Andrea; Stocchi, Fabrizio; Tarnanas, Ioannis; Paul Taylor, John; Teipel, Stefan; Tucci, Federico; Valdes-Sosa, Mitchell; Valdes-Sosa, Pedro; Weiergräber, Marco; Yener, Gorsev; Guntekin, Bahar. - In: ALZHEIMER'S & DEMENTIA. - ISSN 1552-5279. - (2021).

Measures of Resting State EEG Rhythms for Clinical Trials in Alzheimer’s Disease: Recommendations of an Expert Panel

Claudio Babiloni;Claudio Del Percio;Roberta Lizio;Susanna Lopez;Giuseppe Noce;Federico Tucci;
2021

Abstract

The Electrophysiology Professional Interest Area (EPIA) and Global Brain Consortium endorsed recommendations on candidate EEG measures for Alzheimer’s disease (AD) clinical trials. The Panel reviewed the field literature. As most consistent findings, AD patients with mild cognitive impairment and dementia showed abnormalities in peak frequency, power, and “interrelatedness” at posterior alpha (8-12 Hz) and widespread delta (<4 Hz) and theta (4-8 Hz) rhythms in relation to disease progression and interventions. The following consensus statements were subscribed: (i) Standardization of instructions to patients, rsEEG recording methods, and selection of artifact-free rsEEG periods are needed; (ii) Power density and “interrelatedness” rsEEG measures (e.g., directed transfer function, phase lag index, linear lagged connectivity, etc.) at delta, theta, and alpha frequency bands may be use for stratification of AD patients and monitoring of disease progression and intervention; and (iii) International multisectoral initiatives are mandatory for regulatory purposes.
2021
The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART); Alzheimer’s disease (AD); Dementia; Electroencephalography (EEG); Eyes-closed Resting State Condition; Clinical Trials, Biomarkers.
01 Pubblicazione su rivista::01a Articolo in rivista
Measures of Resting State EEG Rhythms for Clinical Trials in Alzheimer’s Disease: Recommendations of an Expert Panel / Babiloni, Claudio; Arakaki, Xianghong; Azami, Hamed; Bennys, Karim; Blinowska, Katarzyna; Bonanni, Laura; Bujan, Ana; Carrillo, Maria C.; Cichocki, Andrzej; de Frutos-Lucas, Jaisalmer; DEL PERCIO, Claudio; Dubois, Bruno; Edelmayer, Rebecca; Egan, Gary; Epelbaum, Stephane; Escudero, Javier; Evans, Alan; Farina, Francesca; Fargo, Keith; Fernández, Alberto; Ferri, Raffaele; Frisoni, Giovanni; Hampel, Harald; Harrington, Michael G.; Jelic, Vesna; Jeong, Jaeseung; Jiang, Yang; Kaminski, Maciej; Kavcic, Voyko; Kilborn, Kerry; Kumar, Sanjeev; Lam, Alice; Lim, Lew; Lizio, Roberta; Lopez, David; Lopez, Susanna; Lucey, Brendan; Maestú, Fernando; Mcgeown, William J.; Mckeith, Ian; Vito Moretti, Davide; Nobili, Flavio; Noce, Giuseppe; Olichney, John; Onofrj, Marco; Osorio, Ricardo; Parra-Rodriguez, Mario; Rajji, Tarek; Ritter, Petra; Soricelli, Andrea; Stocchi, Fabrizio; Tarnanas, Ioannis; Paul Taylor, John; Teipel, Stefan; Tucci, Federico; Valdes-Sosa, Mitchell; Valdes-Sosa, Pedro; Weiergräber, Marco; Yener, Gorsev; Guntekin, Bahar. - In: ALZHEIMER'S & DEMENTIA. - ISSN 1552-5279. - (2021).
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1504607
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 93
  • ???jsp.display-item.citation.isi??? 91
social impact